Phase 3 Study of KHK7580

NCT02549404 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Secondary Hyperparathyroidism

Interventions

DRUG: KHK7580

Sponsor

Kyowa Kirin Co., Ltd.